Trinity Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Trinity Biotech plc
TRIB Stock  USD 0.70  0.01  1.45%   
Trinity Biotech financial statements provide useful quarterly and yearly information to potential Trinity Biotech plc investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Trinity Biotech financial statements helps investors assess Trinity Biotech's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Trinity Biotech's valuation are summarized below:
Gross Profit
21.1 M
Profit Margin
(0.34)
Market Capitalization
18.9 M
Enterprise Value Revenue
1.8558
Revenue
59.1 M
We have found one hundred twenty available fundamental trend indicators for Trinity Biotech plc, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Trinity Biotech plc current market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. As of March 19, 2025, Market Cap is expected to decline to about 4 B. In addition to that, Enterprise Value is expected to decline to about 3.9 B

Trinity Biotech Total Revenue

78.56 Million

Check Trinity Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Trinity Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.6 M, Total Revenue of 78.6 M or Gross Profit of 35.1 M, as well as many indicators such as Price To Sales Ratio of 0.32, Dividend Yield of 0.0095 or Days Sales Outstanding of 88.98. Trinity financial statements analysis is a perfect complement when working with Trinity Biotech Valuation or Volatility modules.
  
Check out the analysis of Trinity Biotech Correlation against competitors.

Trinity Biotech Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets64.9 M68.4 M153.8 M
Slightly volatile
Short and Long Term Debt Total42.8 M77.5 M76.1 M
Pretty Stable
Total Current Liabilities22.6 M17.3 M23.5 M
Slightly volatile
Property Plant And Equipment Net2.1 M2.2 M8.1 M
Slightly volatile
Accounts Payable4.2 M4.5 M12.6 M
Slightly volatile
Cash4 M4.2 M33.3 M
Slightly volatile
Non Current Assets Total22.3 M23.5 M74.4 M
Slightly volatile
Cash And Short Term Investments4 M4.2 M33.3 M
Slightly volatile
Net Receivables18.1 M15.4 M19.5 M
Very volatile
Common Stock Shares Outstanding184.9 M176.1 M60.1 M
Slightly volatile
Liabilities And Stockholders Equity64.9 M68.4 M153.8 M
Slightly volatile
Non Current Liabilities Total82.5 M78.6 M65.1 M
Slightly volatile
Inventory25.5 M22.9 M26.1 M
Pretty Stable
Total Liabilities61.7 M95.9 M85.8 M
Slightly volatile
Total Current Assets69.5 M44.9 M81.1 M
Pretty Stable
Short Term Debt2.1 M2.2 M8.3 M
Pretty Stable
Intangible Assets17.8 M18.7 M40.4 M
Slightly volatile
Common Stock Total Equity994.6 K1.4 M1.1 M
Slightly volatile
Property Plant And Equipment Gross79.8 M76 M28.5 M
Slightly volatile
Common Stock2.4 M2.3 M1.4 M
Slightly volatile
Long Term Debt44 M62.8 M50.8 M
Slightly volatile
Property Plant Equipment9.6 M5.3 M9.3 M
Slightly volatile
Other Liabilities6.2 M5.6 M8.4 M
Very volatile
Current Deferred Revenue42.8 K45 K796.3 K
Slightly volatile
Other Assets4.7 M5 M21.4 M
Pretty Stable
Deferred Long Term Liabilities15.1 M15.9 M37.2 M
Slightly volatile
Short and Long Term Debt179.6 K189 K23.4 M
Very volatile
Long Term Debt Total74.5 M89.8 M94.7 M
Slightly volatile
Capital Surpluse12.9 M14.6 M15.9 M
Slightly volatile
Capital Lease Obligations11.6 M14.5 M7.3 M
Slightly volatile
Non Current Liabilities Other506.8 K478.8 K615.9 K
Slightly volatile
Net Invested Capital26.4 M27.8 M111.5 M
Slightly volatile
Capital Stock1.6 M2.3 M1.4 M
Slightly volatile

Trinity Biotech Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization3.6 M2 M3.5 M
Very volatile
Total Revenue78.6 M65.4 M82.2 M
Pretty Stable
Gross Profit35.1 M22.4 M36 M
Pretty Stable
Other Operating Expenses76.5 M96.5 M77.9 M
Slightly volatile
Cost Of Revenue43.5 M43 M46.3 M
Slightly volatile
Total Operating Expenses33 M53.5 M31.6 M
Slightly volatile
Interest Expense12.3 M11.7 M5.8 M
Slightly volatile
Selling General Administrative23.8 M35.8 M26 M
Slightly volatile
Research Development4.9 M5 M4.4 M
Slightly volatile
Selling And Marketing Expenses23.6 M29 M30.3 M
Very volatile
Non Recurring37.2 M37.6 M44 M
Slightly volatile
Reconciled Depreciation2.8 M1.6 M4.1 M
Slightly volatile

Trinity Biotech Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow7.2 M7.6 M37.3 M
Slightly volatile
Depreciation3.6 M2 M3.5 M
Very volatile
Capital Expenditures877.3 K923.5 K11.9 M
Slightly volatile
End Period Cash Flow4 M4.2 M33.5 M
Slightly volatile
Stock Based Compensation1.4 M2.4 M1.5 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.320.334.3468
Slightly volatile
Dividend Yield0.00950.01680.0154
Slightly volatile
Days Sales Outstanding88.9898.8380.6894
Pretty Stable
Average Payables3.3 M3.8 M3.3 M
Slightly volatile
Stock Based Compensation To Revenue0.03440.03280.0181
Slightly volatile
Capex To Depreciation0.490.523.0443
Slightly volatile
EV To Sales7.557.9587.2608
Slightly volatile
Inventory Turnover3.362.162.1481
Pretty Stable
Days Of Inventory On Hand165175192
Very volatile
Payables Turnover8.3611.077.434
Slightly volatile
Sales General And Administrative To Revenue0.210.240.2565
Pretty Stable
Average Inventory14.2 M22.9 M23.8 M
Very volatile
Research And Ddevelopement To Revenue0.0710.08860.0581
Pretty Stable
Capex To Revenue0.01540.01620.1475
Slightly volatile
Cash Per Share0.02060.02170.4012
Slightly volatile
Payout Ratio0.20.210.2308
Very volatile
Days Payables Outstanding66.9243.6258.2146
Slightly volatile
Intangibles To Total Assets0.290.250.3577
Slightly volatile
Current Ratio2.872.344.1423
Slightly volatile
Receivables Turnover5.944.884.7976
Pretty Stable
Capex Per Share0.00450.00470.1345
Slightly volatile
Average Receivables13.8 M15.9 M16.7 M
Pretty Stable
Revenue Per Share0.320.330.851
Pretty Stable
Interest Debt Per Share0.340.460.6197
Slightly volatile
Debt To Assets1.071.020.5418
Slightly volatile
Graham Number0.50.521.2744
Slightly volatile
Operating Cycle229253270
Very volatile
Days Of Payables Outstanding66.9243.6258.2146
Slightly volatile
Dividend Payout Ratio0.20.210.2308
Very volatile
Long Term Debt To Capitalization1.681.60.7365
Slightly volatile
Total Debt To Capitalization1.471.40.7173
Slightly volatile
Quick Ratio1.91.142.8738
Slightly volatile
Cash Ratio0.210.221.7765
Slightly volatile
Days Of Inventory Outstanding165175192
Very volatile
Days Of Sales Outstanding88.9898.8380.6894
Pretty Stable
Fixed Asset Turnover28.3927.0313.6415
Slightly volatile
Debt Ratio1.071.020.5418
Slightly volatile
Price Sales Ratio0.320.334.3468
Slightly volatile
Asset Turnover0.71.10.6158
Slightly volatile
Gross Profit Margin0.330.310.4014
Pretty Stable

Trinity Biotech Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap4 B5.6 B5.8 B
Very volatile
Enterprise Value3.9 B5.5 B5.8 B
Very volatile

Trinity Fundamental Market Drivers

Cash And Short Term Investments3.7 M

Trinity Upcoming Events

28th of March 2024
Upcoming Quarterly Report
View
4th of July 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Trinity Biotech Financial Statements

Trinity Biotech stakeholders use historical fundamental indicators, such as Trinity Biotech's revenue or net income, to determine how well the company is positioned to perform in the future. Although Trinity Biotech investors may analyze each financial statement separately, they are all interrelated. For example, changes in Trinity Biotech's assets and liabilities are reflected in the revenues and expenses on Trinity Biotech's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Trinity Biotech plc. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue45 K42.8 K
Total Revenue65.4 M78.6 M
Cost Of Revenue43 M43.5 M
Stock Based Compensation To Revenue 0.03  0.03 
Sales General And Administrative To Revenue 0.24  0.21 
Research And Ddevelopement To Revenue 0.09  0.07 
Capex To Revenue 0.02  0.02 
Revenue Per Share 0.33  0.32 
Ebit Per Revenue(0.43)(0.41)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CRMSalesforce
CRMSalesforce
When determining whether Trinity Biotech plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trinity Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trinity Biotech Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trinity Biotech Plc Stock:
How To Invest In Trinity
Details
Is Trinity Stock a good investment?
Details
What is Trinity Biotech's Net Worth?
Details
Largest Health Care Equipment & Supplies Companies
View
Largest Health Care Equipment & Services Companies
View
Check out the analysis of Trinity Biotech Correlation against competitors.
You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trinity Biotech. If investors know Trinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trinity Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.77)
Earnings Share
(2.25)
Revenue Per Share
6.497
Quarterly Revenue Growth
0.032
Return On Assets
(0.08)
The market value of Trinity Biotech plc is measured differently than its book value, which is the value of Trinity that is recorded on the company's balance sheet. Investors also form their own opinion of Trinity Biotech's value that differs from its market value or its book value, called intrinsic value, which is Trinity Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trinity Biotech's market value can be influenced by many factors that don't directly affect Trinity Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Trinity Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Trinity Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trinity Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY